For instance, about 20% of gastric cancers overexpress HER2, resulting in sensitivity to HER2 inhibitors [40], followed by ovarian cancer (16%), while HER2 overexpression occurs in only 1.3% of colon cancers. This evidence concerns the gene ERBB2 and ovarian carcinoma.